Adverse events · chronic pruritus of unknown origin
It is very uncertain whether serlopitant 1 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events (split-mouth) · People with symptomatic, biopsy-confirmed oral lichen planus (OLP); not concurrently receiving other OLP treatment
Topical triamcinolone acetonide led to lower adverse events (split-mouth) compared with cryotherapy; GRADE not reported.
1 finding from 1 review
Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
1 finding from 1 review
Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
1 finding from 1 review
Interventions for managing halitosis 2019 · Cochrane All outcomesmean 2 weeks
Adverse events (Table 6). Risk with placebo mouthwash: None reported. Risk with halita mouthwash: tongue staining was seen in patients who gargled, rather than rinsed. 40 participants (1 RCT). Certainty: VERY LOW.
1 study · 40 participants
Very low
Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
1 finding from 1 review
Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
1 finding from 1 review
Interventions for managing halitosis 2019 · Cochrane All outcomesmean 8 days
Adverse events (Table 12). Risk with Perio-plus mouthrinse: 1 patient reported unpleasant feeling after the use of the product; there were no severe adverse events reported. Risk with halita mouthrinse: 1 patient…
1 study · 36 participants
Very low
Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
1 finding from 1 review
Patil 2017 reported burning mucosa and drying of mouth in a few subjects using the control drug (chlorhexidine) and no adverse effects were reported in the intervention group (G32 tablets).
1 study · 40 participants
GRADE not reported
Adverse events · Adolescents and adults aged over 16 years with clinical or self-assessed halitosis of oral origin; excluding induced or physiological…
1 finding from 1 review
Adverse events · primary VUR
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · primary VUR
Antibiotic prophylaxis showed no clear difference in adverse events compared with surveillance or no treatment (moderate certainty).
1 finding from 1 review
Adverse events: death · idiopathic steroid‐resistant nephrotic syndrome in children
Calcineurin inhibitor showed no clear difference in adverse events: death compared with IV cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events: Vomiting · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether IV changes adverse events: vomiting compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review
Alopecia · idiopathic steroid‐resistant nephrotic syndrome in children
IV showed no clear difference in adverse events: alopecia compared with oral cyclophosphamide (low certainty).
1 finding from 1 review
Adverse events: hypertension · idiopathic steroid‐resistant nephrotic syndrome in children
IV cyclophosphamide may leads to lower adverse events: hypertension compared with oral cyclophosphamide plus IV dexamethasone (low certainty).
1 finding from 1 review
Adverse events: infection · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether cyclosporin changes adverse events: infection compared with placebo or no treatment (very low certainty).
1 finding from 1 review
Adverse events: hypotension · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: hypotension compared with cyclosporin/prednisolone (very low certainty).
1 finding from 1 review